Inhaled pre-prandial human insulin with the AERx® iDMS plus metformin versus rosiglitazone plus metformin in type 2 diabetes: a 26-week, open-label, multicentre, randomised, parallel trial to investigate efficacy and safety.
Phase of Trial: Phase III
Latest Information Update: 04 Mar 2017
At a glance
- Drugs Insulin (Primary) ; Metformin; Metformin/pioglitazone; Rosiglitazone
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 10 Jun 2017 Biomarkers information updated
- 25 Apr 2012 Planned number of patients changed from 345 to 448 as reported by European Clinical Trials Database record.
- 25 Apr 2012 Official Title amended as reported by European Clinical Trials Database record.